Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide
Obesity · 2026
DOI: 10.1002/oby.70179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2026. Verfasst von Sarah R Barenbaum und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, Ne…. Hauptthemen laut MEDLINE: Tirzepatide, Weight Loss, Obesity, Glucagon-Like Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Clinical and Translational Science Center, Weill Cornell Medical College, Clinical and Translational Science Center, Weill Cornell Medicine.
Abstract (Originalsprache)
Objective
This study compared weight‐loss outcomes in patients prescribed tirzepatide by weight‐loss status and assessed results among patients transitioning from semaglutide.
Methods
This retrospective cohort study analyzed 6‐month weight‐loss outcomes in adults treated with tirzepatide between May 2022 and January 2023. Patients were classified as weight‐reduced if they had lost ≥ 10% total body weight (TBW) before starting tirzepatide. Among those who switched from therapeutic semaglutide (≥ 1.7 mg weekly for ≥ 1 month), reasons for switching were categorized as non‐response (< 5% weight loss after ≥ 3 months), plateau (≥ 5% loss followed by weight stabilization), or other.
Results
Of 941 charts, 293 (31.1%) met inclusion criteria (65% female; mean age 52 years; mean BMI 36.15 kg/m 2 ). Weight‐reduced patients ( n = 133) lost 7.2% TBW versus 10.3% in non‐weight‐reduced patients ( n = 160; p < 0.001). When analyses were stratified by type 2 diabetes (T2D) status, this difference remained significant among patients without T2D. Sixty‐one patients switched from semaglutide due to non‐response or plateau and lost 5.3% TBW. Those switching at a plateau ( n = 28) lost 8.1% versus 2.9% for non‐responders ( n = 33; p < 0.001).
Conclusions
Tirzepatide produced meaningful weight loss across groups but outcomes varied based on weight‐reduction status, T2D status, and prior response to semaglutide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, New York, USA.
- Weill Cornell Medical College, New York, New York, USA.
- Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA.
- Department of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Förderung
- Clinical and Translational Science Center, Weill Cornell Medical College
- Clinical and Translational Science Center, Weill Cornell Medicine
Zitieren
APA
Barenbaum, S. R., Gonzalez, A., Verzani, Z., Zhao, A. S., & Shukla, A. P. (2026). Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide. Obesity. https://doi.org/10.1002/oby.70179
Vancouver
Barenbaum SR, Gonzalez A, Verzani Z, Zhao AS, Shukla AP. Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide. Obesity. 2026. doi:10.1002/oby.70179
BibTeX
@article{Barenbaum2026,
author = {Barenbaum, Sarah R and Gonzalez, Ariel and Verzani, Zoe and Zhao, Alice S and Shukla, Alpana P},
title = {Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70179}
}
EUVIMED